Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded product | product | 68180-866 | D | Discontinued by firm | 2026-07-31 | ||
| excluded package | package | 68180-866 | 68180-866-13 | D | Discontinued by firm | 2026-07-31 |
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A201585-001 | BLISOVI FE 1.5/30 | ETHINYL ESTRADIOL; NORETHINDRONE ACETATE | 0.03MG;1.5MG | TABLET / ORAL-28 | AB | 2015-11-18 |
| Application-product | TE code |
|---|---|
| A201585-001 | AB |
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| BLISOVI FE 1.5/30 | NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL | Lupin Pharmaceuticals, Inc. | a0ba9371-46c5-4291-8409-491911e255ab | 2025-05-08 | Boxed warning, Warnings, Adverse reactions |
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including Blisovi Fe 1.5/30, are contraindicated in women who are over 35 years of age and smoke (see CONTRAINDICATIONS and WARNINGS) .
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity, and diabetes. Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks. The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined. Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population (adapted from References 8 and 9 with the author's permission). For further information, the reader is referred to a text on epidemiological methods. 1. Thromboembolic Disorders and Other Vascular Problems a. Myocardial Infarction An increased risk of myocardial infarction has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. The relative risk of heart attack for current oral contraceptive users has been estimated to be two to six (10-16). The risk is very low under the age of 30. Smoking in combination with oral contraceptive use has been shown to contribute su...
TABLE III: ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN BY FERTILITY CONTROL METHOD ACCORDING TO AGE Adapted from H.W. Ory, Reference 41 Method of control and outcome 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 No fertility control methodsDeaths are birth related 7.0 7.4 9.1 14.8 25.7 28.2 Oral contraceptives non-smokerDeaths are method related 0.3 0.5 0.9 1.9 13.8 31.6 Oral contraceptives smoker 2.2 3.4 6.6 13.5 51.1 117.2 IUD 0.8 0.8 1.0 1.0 1.4 1.4 Condom 1.1 1.6 0.7 0.2 0.3 0.4 Diaphragm/spermicide 1.9 1.2 1.2 1.3 2.2 2.8 Periodic abstinence 2.5 1.6 1.6 1.7 2.9 3.6
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
ADVERSE REACTIONS An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS section) : Thrombophlebitis Arterial thromboembolism Pulmonary embolism Myocardial infarction Cerebral hemorrhage Cerebral thrombosis Hypertension Gallbladder disease Hepatic adenomas or benign liver tumors Post Marketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 to 1.12 (Figure 1) (70-74). Three studies compared breast cancer risk between current or recent COC users (
| Field | Values |
|---|---|
| Rxcui | 259176, 1359022, 1359023, 1729516 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68180-866-73 | BLISOVI FE 1.5/30 | 1 in 1 POUCH | KIT | 1 | 8 | |
| 68180-866-73 | BLISOVI FE 1.5/30 | 3 in 1 CARTON | KIT | 3 | 8 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 68180-866-11 | EA - Each | 68180-866 | cd1269c0-8a11-498d-9af5-96cdabd1ccc3 | 1 | 2016-02-04 |
| 68180-866-13 | EA - Each | 68180-866 | 98f36089-bbd8-42eb-85dc-73e56c7a5f9e | 1 | 2016-02-04 |
| 68180-866-71 | EA - Each | 68180-866 | 0c34f7d1-a95f-4e9e-b01d-6c538a6c647c | 1 | 2019-12-10 |
| 68180-866-73 | EA - Each | 68180-866 | 66e63d0e-6c80-469a-8047-93495f76fe42 | 1 | 2019-12-10 |
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 1729516 | {21 (ethinyl estradiol 0.03 MG / norethindrone acetate 1.5 MG Oral Tablet) / 7 (ferrous fumarate 75 MG Oral Tablet) } Pack [Blisovi 21 Fe 1.5/30 28 Day Pack] | BPCK | a0ba9371-46c5-4291-8409-491911e255ab | 8 |
| 1359023 | {21 (ethinyl estradiol 0.03 MG / norethindrone acetate 1.5 MG Oral Tablet) / 7 (ferrous fumarate 75 MG Oral Tablet) } Pack | GPCK | a0ba9371-46c5-4291-8409-491911e255ab | 8 |
| 1729516 | Blisovi 21 Fe 1.5/30 28 Day Pack | PSN | a0ba9371-46c5-4291-8409-491911e255ab | 8 |
| 1359023 | Eth estra-Noreth Ac 0.03-1.5 MG (21) Oral Tablet / Ferr fum 75 MG (7) Oral Tablet 28 Day Pack | PSN | a0ba9371-46c5-4291-8409-491911e255ab | 8 |
| 259176 | ferrous fumarate 75 MG Oral Tablet | PSN | a0ba9371-46c5-4291-8409-491911e255ab | 8 |
| 1359022 | norethindrone acetate 1.5 MG / ethinyl estradiol 30 MCG Oral Tablet | PSN | a0ba9371-46c5-4291-8409-491911e255ab | 8 |
| 1359022 | ethinyl estradiol 0.03 MG / norethindrone acetate 1.5 MG Oral Tablet | SCD | a0ba9371-46c5-4291-8409-491911e255ab | 8 |
| 259176 | ferrous fumarate 75 MG Oral Tablet | SCD | a0ba9371-46c5-4291-8409-491911e255ab | 8 |
| 1729516 | Blisovi 21 Fe 1.5/30 28 Day Pack | SY | a0ba9371-46c5-4291-8409-491911e255ab | 8 |
| 1359022 | ethinyl estradiol 30 MCG / norethindrone acetate 1.5 MG Oral Tablet | SY | a0ba9371-46c5-4291-8409-491911e255ab | 8 |
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 68180-866-73 | 68180086673 | 3 POUCH in 1 CARTON (68180-866-73) / 1 BLISTER PACK in 1 POUCH / 1 KIT in 1 BLISTER PACK | 3 pouch | 2019-11-07 | 0000-00-00 | No | No | Current |